Gutturbes

Gutturbes is a pharmaceutical product that contains the active ingredient flurbiprofen, a non‑steroidal anti‑inflammatory drug (NSAID). It is marketed in the European Union and is intended for oropharyngeal administration. While the specific strength and dosage form are not disclosed, Gutturbes belongs to the analgesic and anti‑inflammatory therapeutic class and works by inhibiting cyclooxygenase enzymes to reduce pain and inflammation through systemic absorption and is prescribed by healthcare professionals.

Gutturbes, containing flurbiprofen, is used for the relief of mild to moderate pain and the reduction of inflammation associated with various musculoskeletal conditions. It is commonly applied in the oropharyngeal area for localized therapeutic effect. - Relief of dental or oral pain, such as after tooth extraction. - Management of sore throat or inflammatory conditions of the mouth and throat. - Adjunctive treatment of musculoskeletal disorders, including sprains, strains, and minor joint inflammation. - Short‑term control of postoperative pain following oral surgery. - Reduction of inflammation in temporomandibular joint disorders.

The safety profile of flurbiprofen, the active component of Gutturbes, includes a range of adverse effects that vary in frequency and severity.

Common: - Mild gastrointestinal discomfort such as nausea or dyspepsia. - Transient headache or dizziness. - Local irritation or burning sensation in the mouth or throat. - Taste alteration or metallic aftertaste.

Serious: - Gastrointestinal ulceration or bleeding. - Severe allergic reactions, including rash, angioedema, or anaphylaxis. - Renal impairment or reduced kidney function.

When considering Gutturbes, clinicians and patients should observe several precautionary measures to minimize risk and ensure appropriate use. - Assess for a history of peptic ulcer disease or gastrointestinal bleeding. - Use caution in patients with cardiovascular disease or hypertension. - Evaluate renal and hepatic function before initiating therapy. - Avoid use during the third trimester of pregnancy unless clearly indicated. - Monitor for signs of hypersensitivity, especially in individuals with known NSAID allergy. - Limit duration of treatment to the shortest effective period. - Do not exceed recommended dosing frequency.

Flurbiprofen may interact with other medications, influencing efficacy or safety. Relevant interactions are grouped below.

Avoid: - Concurrent use with other NSAIDs or aspirin, which can increase bleeding risk. - Combination with anticoagulants such as warfarin or direct oral anticoagulants. - Co‑administration with selective serotonin reuptake inhibitors (SSRIs) or other serotonergic agents.

Use with caution: - Concurrent use with antihypertensive drugs, as NSAIDs may reduce their effectiveness. - Combination with diuretics or ACE inhibitors, potentially affecting renal function. - Use with corticosteroids may increase risk of gastrointestinal complications.